Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
lunedì, ottobre 26
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
iRadimed Corp
IRMD
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$85.82
-1.82
-2.08%
Ult. Agg.: Oct 23, 6:05 AM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Dividendi
Confronta
Opzioni
Rapporto azionario
Utili:
I risultati di Q3 2026 tra 5 giorni da adesso in ven ott 30th, prima dell'apertura del mercato
iRadimed Financials
iRadimed (IRMD) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
iRadimed Q2 Adj. EPS $0.46 Beats $0.42 Estimate, Sales $20.466M Beat $20.350M Estimate
Benzinga Newsdesk
PRO
iRadimed Sees Q3 Adj EPS $0.54-$0.59 vs $0.52 Est; Sees Sales $23.000M-$24.500M vs $23.650M Est
iRadimed (NASDAQ:IRMD) is looking for Q3 Adj EPS of $0.54-$0.59 vs $0.52 analyst estimate. sees sales of $23.000 million-$24.500 million vs $23.650 million analyst estimate.
Benzinga Newsdesk
PRO
iRadimed Affirms FY2026 GAAP EPS Guidance of $1.90-$2.05 vs $1.91 Est
iRadimed (NASDAQ:IRMD) affirms FY2026 GAAP EPS guidance from $1.90-$2.05 to $1.90-$2.05 vs $1.91 analyst estimate..
Benzinga Newsdesk
CORRECTION: iRadimed Raises FY2026 Adj EPS Guidance from $2.06-$2.21 to $2.09-$2.24 vs $2.08 Est; Affirms FY2026 Sales Guidance of $91.000M-$96.000M vs $91.300M Est
iRadimed (NASDAQ:IRMD) raises FY2026 Adj EPS guidance from $2.06-$2.21 to $2.09-$2.24 vs $2.08 analyst estimate. Raises FY2026 sales outlook from $91.000 million-$96.000 million to $91.000 billion-$96.000 billion vs
Benzinga News-desk
PRO
iRadimed Sees Q3 GAAP EPS $0.49-$0.54 vs $0.49 Est
iRadimed (NASDAQ:IRMD) is looking for Q3 GAAP EPS of $0.49-$0.54 vs $0.49 analyst estimate..
Benzinga Newsdesk
PRO
iRadimed Affirms FY2026 GAAP EPS Guidance of $1.90-$2.05 vs $1.91 Est
iRadimed (NASDAQ:IRMD) affirms FY2026 GAAP EPS guidance from $1.90-$2.05 to $1.90-$2.05 vs $1.91 analyst estimate..
Benzinga Newsdesk
